Literature DB >> 25749940

Regulatory, legislative, and policy updates with anticoagulant use.

John Fanikos1, Leo F Buckley, Ahmed Aldemerdash, Kimberly J Terry, Gregory Piazza, Jean M Connors, Samuel Z Goldhaber.   

Abstract

Thromboembolism afflicts millions of patients annually in the United States and is associated with a significant cost burden. Recent advances in oral anticoagulation have provided clinicians with more options for management of these diseases. Accordingly, regulatory, legislative, and policy-making organizations have intervened with the aim of improving patient outcomes, ensuring patient safety, and reducing costs. There have been a number of recent developments in surveillance, litigation, and regulatory oversight that clinicians should recognize. In this review article we summarize key updates related to the management of anticoagulant therapy as it relates to thrombosis prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25749940     DOI: 10.1007/s11239-015-1198-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  35 in total

1.  Developing the Sentinel System--a national resource for evidence development.

Authors:  Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

Review 2.  Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management.

Authors:  J E Ansell; R Hughes
Journal:  Am Heart J       Date:  1996-11       Impact factor: 4.749

Review 3.  Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Authors:  Stacie B Dusetzina; Ashley S Higashi; E Ray Dorsey; Rena Conti; Haiden A Huskamp; Shu Zhu; Craig F Garfield; G Caleb Alexander
Journal:  Med Care       Date:  2012-06       Impact factor: 2.983

4.  Dabigatran: how the drug company withheld important analyses.

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2014-07-23

5.  FDA starts new light-touch inspections for some imports.

Authors:  Stephen Barlas
Journal:  P T       Date:  2014-06

6.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

7.  Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009).

Authors:  Wei Huang; Robert J Goldberg; Frederick A Anderson; Catarina I Kiefe; Frederick A Spencer
Journal:  Am J Med       Date:  2014-05-06       Impact factor: 4.965

8.  Association of timely administration of prophylactic antibiotics for major surgical procedures and surgical site infection.

Authors:  Mary T Hawn; Kamal M Itani; Stephen H Gray; Catherine C Vick; William Henderson; Thomas K Houston
Journal:  J Am Coll Surg       Date:  2008-03-04       Impact factor: 6.113

9.  Heparin crisis 2008: a tipping point for increased FDA enforcement in the pharma sector?

Authors:  Larry Rosania
Journal:  Food Drug Law J       Date:  2010       Impact factor: 0.619

10.  Compliance with acute stroke care quality measures in hospitals with and without primary stroke center certification: the North Carolina Stroke Care Collaborative.

Authors:  Anna M Johnson; Larry B Goldstein; Paige Bennett; Emily C O'Brien; Wayne D Rosamond
Journal:  J Am Heart Assoc       Date:  2014-04-10       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.